Abb Vie Deutschland Gmbh & Co. Kg

Abbvie Inc.

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Boehringer Ingelheim International Gmbh

Abbvie Deutschland Gmbh and Co Kg

Ulrich Ebert

Heinz Hillen

Stefan Barghorn

Andreas R Striebinger

Boris Labkovsky

Patrick Keller

Chung-Ming Hsieh

Simone Giaisi

Martin Schmidt

Volker Nimmrich

John E Harlan

Ralf Loebbert

Lorenzo Benatuil

Jijie Gu

Reinhold Mueller

Enrico L Digiammarino

Gerard B Fox

Feng Luo

Zhen Wu

Adrian Tersteegen

Martin Hendrix

Lars Bärfacker

Christina Erb

Heike Heckroth

Marja Van Kampen

Frank-Thorsten Hafner

Dagmar Karthaus

Franz-Josef Van Der Staay

Nicole Teusch

Edward T Olejniczak

Achim Möller

Ana Pereda-Lopez

Thomas F Holzman

Alfred Hahn

Bettina Beyreuther

Carsten Krantz

Gerhard Gross

Andreas Draguhn

Claus Bruhl

Christine Grimm

Rohinton P Edalji

Liping Yu

Yan-Hong Liu

Andreas Striebinger

Anti-A&#x3b2; globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A&#x3b2; globulomer antibodies having a binding affinity to A&#x3b2;(20-42) globulomer that is greater than the binding affinity of the antibody to A&#x3b2;(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.

Anti-A&#x3b2; globulomer 4D10 antibodies

The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.

Monoclonal antibodies against amyloid beta protein and uses thereof

The present invention relates to amyloid-beta (A&#x3b2;) binding proteins. Antibodies of the invention have high affinity to &#x39b;&#x3b2;(20-42) globulomer or any &#x39b;&#x3b2; form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.

Amyloid-beta binding proteins

The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.

A&#x3b2; conformer selective anti-A&#x3b2; globulomer monoclonal antibodies

The present invention relates to amyloid-beta (A&#x3b2;) binding proteins. Antibodies of the invention have high affinity to A&#x3b2;(20-42) globulomer or any A&#x3b2; form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.

Anti-A&#x3b2; globulomer 7C6 antibodies

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

Abeta conformer selective anti-Abeta globulomer monoclonal antibodies

The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor multimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER.

AGER-peptides and use thereof

The present invention relates to a method for the treatment of an amyloidosis such as Alzheimer's disease in a subject in need thereof, characterized in that it comprises administering an inhibitor of the interaction between A&#x3b2; globulomer and the P/Q type voltage-gated presynaptic calcium channel to said subject.

Method for the treatment of amyloidoses

Growing community of inventors

Mannheim, Germany

Ulrich Ebert